ClinicalTrials.gov record
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC

ClinicalTrials.gov ID: NCT04919811

Public ClinicalTrials.gov record NCT04919811. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 6, 2026, 8:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of Taletrectinib in Patients With Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors

Study identification

NCT ID
NCT04919811
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Nuvation Bio Inc.
Industry
Enrollment
217 participants

Conditions and interventions

Interventions

  • Taletrectinib Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 31, 2021
Primary completion
Jun 10, 2025
Completion
Nov 30, 2027
Last update posted
Jan 6, 2026

2021 – 2027

United States locations

U.S. sites
20
U.S. states
9
U.S. cities
20
Facility City State ZIP Site status
Beverly Hills Cancer Center Beverly Hills California 90211
The Oncology Institute of Hope and Innovation Glendale California 91204
Moores Cancer Center at UC San Diego La Jolla California 92037
Keck Medicine of University of Southern California Los Angeles California 90089
UCI Medical Center Orange California 92868
Ventura County Hematology-Oncology Specialists Oxnard California 93030
SCRI - Florida Cancer Specialists South Fort Meyers Florida 33901
Memorial Cancer Institute at Memorial Hospital East Hollywood Florida 33021
Cancer Specialists of North Florida Jacksonville Florida 92868
Memorial Cancer Institute at Memorial Hospital West Pembroke Pines Florida 33028
SCRI - Hematology Oncology Clinic Baton Rouge Louisiana 70809
Mayo Clinic Rochester Minnesota 55902
Center for Cancer Research Brick New Jersey 08724
Cleveland Clinic Foundation Cleveland Ohio 44195
SCRI - Tennessee Oncology Nashville Tennessee 37203
Texas Oncology, P.A. Dallas Texas 75246
Renovatio Clinical El Paso Texas 19915
MD Anderson Cancer Center Houston Texas 77030
Renovatio Clinical The Woodlands Texas 77380
Northwest Medical Specialties, PLLC Tacoma Washington 98405

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 57 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04919811, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 6, 2026 · Synced May 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04919811 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →